Current Allergy and Clinical Immunology - March 2008

More documents

Recommendations

Info

$latex allerGy revisited : a review - Allergy Society of South Africa$

$Cross-reactivity of food allegens with latex - ALLSA$

ALLSA MEMBERSHIP 2008Support your society, it supports allergology in South AfricaALLSA remains one of the world’s most pro-active and innovative allergy societies. Our pioneering website andpatient information resources have spurred other national societies to follow suit.ALLSA relies on an active membership base to continue to provide excellent resources to healthcare workers inSouthern Africa. We welcome new members from all over Southern Africa and membership is open to all healthcareworkers with an interest in allergology. Our current membership includes medical practitioners (general practitioners,physicians, pulmonologists, ENT specialists, dermatologists, ophthalmologists, paediatricians andanaesthetists), nurses, dieticians, medical technologists, pharmaceutical industry staff and medical students .Membership currently costs only R200 annually; this is a tax-deductible expense.Members enjoy a number of privileges which include:• The highly rated ALLSA journal – Current Allergy & Clinical Immunology, which is edited by Profs Weinberg andZar, and published quarterly. This journal is available on-line.• Access to ALLSA’s comprehensive allergy website at www.allergysa.org.• On-line CPD accreditation.• Patient information guides and leaflets on common allergic disorders.• Discounted ALLSA congress registration fees for our annual congress.• Regional allergy courses, meetings and journal clubs.• Support with examination preparation for the Diploma in Allergology of the Colleges of Medicine of SA.• Access to allergy research funding and annual ALLSA research awards of up to R50 000 per research study.For more details on membership and privileges please contact Ruwayda Adams on tel 021-447-9019,fax 021-448-0846, or e-mail enquiries to mail@allergysa.orgPlease cut out the membership application form and post together with your payment.ALLSA Membership ApplicationR200 annual subscription✃Dr/Sr/Mr/Mrs/Ms: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Address: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .E-mail address:. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Phone: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fax: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Speciality: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Special Interests: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Comments: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Post to: Allergy Society of South Africa, PO Box 88, Observatory 7935Direct debit details:Standard Bank: RondeboschSort Code: 02-50-09Account Number: 07 149 1821Cheques payable to Allergy Society of South AfricaFor direct deposits: Kindly fax your bank deposit slip as proof of payment (Fax No. 021-448-0846)Current Allergy & Clinical Immunology, March 2008 Vol 21, No. 1 55
PRODUCT NEWSNASONEX IS NOW INDICATED FROMTHE AGE OF 2 YEARS!Nasonex Aqueous Nasal Spray is indicated for use inadults, adolescents and children between the agesof 2 and 11 years to treat the symptoms of seasonalallergic or perennial allergic rhinitis.In patients who have a history of moderate to severesymptoms of seasonal allergic rhinitis, prophylactictreatment with Nasonex Aqueous Nasal Spray is recommendedprior to the anticipated start of the pollenseason.Dosage and directions for useAdults and adolescents: The usual recommendeddose for prophylaxis and treatment is two sprays (50µg/spray) into each nostril once daily (total dose200 µg). Once symptoms are controlled, dose reductionto one spray into each nostril (total dose 100 µg)may be effective in some patients for maintenance.Children between the ages of 2 and 11 years: Theusual recommended dose is one spray (50 µg/spray)in each nostril once daily (total dose 100 µg).For more information contactGary Vine,Schering-Plough (Pty) Ltd,011-922-3300.PIMECROLIMUS CREAM 1% IN ATOPICDERMATITIS: A 6-MONTH, OPEN-LABELTRIAL IN PAEDIATRIC PATIENTSPimecrolimus, a new, non-steroid, inflammatorycytokineinhibitor, has been shown to prevent progressionto flare in atopic dermatitis (AD) and toimprove long-term disease control when applied as a1% cream. In this 6-month, open-label, multinationalstudy, 177 infants aged 3-23 months and 489 childrenaged 2-17 years, with mild to severe AD, were included.The study was designed to evaluate the efficacyand safety of pimecrolimus cream 1% used as a firstlinetreatment. Treatment consisted of an initial bidregimen, for as long as signs and symptoms of diseasepersisted; this was followed by treatment asrequired at the first signs and symptoms of AD.Emollients were allowed as per the physician's normalpractice, and topical corticosteroids could be used totreat severe flares at the discretion of the physician.Efficacy was assessed by evaluations of pruritus, andtotal-body and facial Investigators' GlobalAssessment (IGA). Results from the first return visit(day 7) showed an improvement from baseline of 1in total-body and facial IGA for infants (59.1% and72.8% of patients, respectively) and children (59.3%and 62.2%, respectively). Pruritus was absent or mildin 67.8% and 65.4% of infants and children, respectively.This level of improvement in the patient populationwas maintained throughout the 6-month study.Adverse events occurred in 75.7% of infants and71.1% of children. Most adverse events were commonchildhood illnesses that would be expected inthis population (e.g. nasopharyngitis (infants 22.0%,children 12.8%), upper respiratory tract infection(infants 18.6%, children 11.9%) and cough (infants8.5%, children 10.1%)). Concerning pimecrolimus'slocal tolerability, application-site burning occurred in2.3% of infants and 7.0% of children, and local pruritusoccurred in 0.6% infants and 1.0% children.Application-site reactions were most frequentlyreported during the first 6 weeks of treatment andwere mild to moderate in intensity. In conclusion,pimecrolimus cream 1% was effective in the treatmentof the early signs and symptoms of AD (including pruritus)in infants and children, and demonstrated agood safety profile.Reference available on request. Contact Thoko Nzama, 011-929-911156 Current Allergy & Clinical Immunology, March 2008 Vol 21, No. 1
Page 6 and 7: with memory T-cell phenotypes. 18 T
Page 8 and 9: Burkholderia cepacia may be serious
Page 10 and 11: Fig. 4. Sweat test.Stage 3Lymphocyt
Page 12 and 13: AN UPDATE OF THE PRIMARY ANTIBODYDI
Page 14 and 15: lymphocytes refine the primary anti
Page 16 and 17: ange of haematological problems occ
Page 19 and 20: SEVERE COMBINED IMMUNODEFICIENCY(SC
Page 21 and 22: tinely from all neonates at birth i
Page 23 and 24: tions to the use of antiviral drugs
Page 25 and 26: therapeutic IVIG are complex. In ma
Page 27 and 28: TABLE III. Recommendations for the
Page 29 and 30: 5. Ballow M. Mechanisms of action o
Page 31 and 32: Fig. 2. Surface epidermis with unde
Page 33 and 34: sone). Unfounded steroidophobia is
Page 35 and 36: tant reaction fades by 72 hours. Fo
Page 37 and 38: try worker: case report and review
Page 39 and 40: ➞Step up if needed (first check i
Page 41 and 42: NEWSALLSA hosts a symposium at the
Page 43 and 44: PRODUCT NEWSNEW DESIGN FOR SYMBICOR
Page 45: PRODUCT NEWSBOEHRINGER INGELHEIM LA
Page 49 and 50: PRODUCT NEWSNew Nestlé NAN H.A. 1
Page 51: INSTRUCTIONS FOR AUTHORSCurrent All

Current Allergy and Clinical Immunology - March 2008

Create successful ePaper yourself

Delete template?

Save as template?